Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders.
Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered.
Smith
Caroline L
CL
Centre for Clinical Pharmacology and Therapeutics, British Heart Foundation Laboratories, Department of Medicine, University College London, London WC1E6JJ, UK. c.l.smith@ucl.ac.uk
Vallance
Patrick
P
D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D003935:Diagnostic Techniques, Cardiovascular; D006801:Humans
D015415:Biomarkers; C018524:N,N-dimethylarginine; D001120:Arginine